Evolutionary Genomics, Inc. (FNAM) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FNAM representa a Evolutionary Genomics, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Evolutionary Genomics, Inc. (FNAM) Resumen de Asistencia Médica y Tuberías
Evolutionary Genomics, Inc. is a biotechnology firm focused on gene research and identification, utilizing its Adapted Traits Platform to enhance agricultural productivity through genetic insights, positioning itself as a key player in the intersection of agriculture and genomics.
Tesis de Inversión
Evolutionary Genomics, Inc. presents a unique investment thesis driven by its proprietary Adapted Traits Platform, which is poised to capitalize on the growing demand for genetically enhanced crops. The global biotechnology market is projected to reach $727.1 billion by 2025, with agricultural biotechnology being a significant contributor to this growth. The company's focus on enhancing crop traits aligns with industry trends towards sustainability and food security, potentially driving revenue growth as it expands its client base among governmental and commercial entities. However, the company faces risks associated with its small size and limited resources, which could impact its ability to scale operations and compete effectively. The absence of a dividend and a negative P/E ratio further highlights the need for careful consideration of its financial health and market position.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap: $0.00B indicates a nascent stage of growth with potential for future development.
- P/E Ratio: -0.00 reflects current financial challenges, emphasizing the need for strategic growth.
- Beta: -0.14 suggests low volatility compared to the market, indicating stability in uncertain times.
- Employee count: 2, highlighting a lean operational structure focused on niche research.
- No dividend yield, which aligns with the company's reinvestment strategy for growth.
Competidores y Pares
Fortalezas
- Innovative Adapted Traits Platform for genetic research.
- Strong focus on sustainability and food security.
- Niche expertise in agricultural biotechnology.
Debilidades
- Limited resources with only two employees.
- Negative P/E ratio indicating financial challenges.
- Dependence on external funding for research initiatives.
Catalizadores
- Upcoming: Potential partnerships with governmental organizations to enhance research funding.
- Ongoing: Development of the Adapted Traits Platform to attract commercial clients.
- Upcoming: Expansion into international markets to tap into new agricultural needs.
Riesgos
- Potential: Regulatory challenges that could delay research and product development.
- Ongoing: Financial instability due to negative P/E ratio and limited resources.
- Potential: Competition from larger biotechnology firms with more resources.
Oportunidades de crecimiento
- Growth opportunity 1: The global agricultural biotechnology market is projected to reach $49.5 billion by 2025, driven by increasing demand for genetically modified crops. Evolutionary Genomics can capitalize on this trend through its Adapted Traits Platform, offering tailored solutions for enhancing crop resilience and yield.
- Growth opportunity 2: With the rising emphasis on sustainable agricultural practices, Evolutionary Genomics can expand its research initiatives to include gene editing technologies like CRISPR. This could enhance its product offerings and attract collaborations with larger agricultural firms looking for innovative solutions.
- Growth opportunity 3: The increasing investment in agricultural research from governmental and non-profit organizations provides a significant opportunity for Evolutionary Genomics to secure funding and partnerships. By aligning its research goals with these entities, the company can enhance its visibility and market reach.
- Growth opportunity 4: The ongoing global food security crisis presents an urgent need for advancements in crop genetics. Evolutionary Genomics can position itself as a leader in developing traits that improve crop resilience against climate variability, thereby tapping into a critical market need.
- Growth opportunity 5: Expansion into international markets, particularly in developing regions where agricultural innovation is crucial, can provide Evolutionary Genomics with new revenue streams. By adapting its technology to local agricultural challenges, the company can enhance its global footprint.
Oportunidades
- Growing global market for agricultural biotechnology.
- Potential partnerships with governmental and non-profit organizations.
- Expansion into international markets with agricultural needs.
Amenazas
- Intense competition from larger biotechnology firms.
- Regulatory challenges in genetic research and modification.
- Market volatility impacting funding and investment.
Ventajas competitivas
- Proprietary Adapted Traits Platform providing a unique technological advantage.
- Focus on niche market of positively selected genes, reducing direct competition.
- Expertise in agricultural biotechnology enhances credibility and attractiveness to partners.
Acerca de FNAM
Founded in 1990 and headquartered in Castle Rock, Colorado, Evolutionary Genomics, Inc. is a biotechnology company dedicated to the research and identification of positively selected genes across humans, animals, and commercial crops. The company has developed the Adapted Traits Platform, a sophisticated technology designed to pinpoint genes that can enhance various crop traits including yield, sugar content, biomass, drought tolerance, and resistance to pests and diseases. This platform not only serves agricultural needs but also caters to governmental organizations and non-profit foundations, reflecting its commitment to advancing agricultural science and sustainability. With a small team of just two employees, Evolutionary Genomics operates in a niche market, focusing on the intersection of genomics and agriculture. The company’s innovative approach positions it uniquely within the biotechnology sector, as it seeks to leverage genetic advancements to meet the growing global demand for food security and sustainable agricultural practices. Its research initiatives are essential in addressing the challenges posed by climate change and population growth, making its contributions vital for future agricultural developments.
Qué hacen
- Research and identify positively selected genes in humans, animals, and commercial crops.
- Develop the Adapted Traits Platform for enhancing crop traits.
- Focus on traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance.
- Serve governmental organizations, non-profit foundations, and commercial entities.
- Contribute to advancements in agricultural biotechnology and sustainability.
Modelo de Negocio
- Generate revenue through research contracts with governmental and non-profit organizations.
- Collaborate with commercial entities to develop tailored genetic solutions.
- Leverage proprietary technology to enhance agricultural productivity and sustainability.
Contexto de la Industria
The biotechnology industry, particularly in the agricultural sector, is experiencing significant growth driven by advancements in genetic research and increasing demands for sustainable farming practices. As global populations rise and climate change impacts agricultural productivity, companies like Evolutionary Genomics are positioned to offer innovative solutions through genetic enhancement of crops. The market for agricultural biotechnology is expected to grow at a CAGR of 10.5% from 2020 to 2025, indicating a robust competitive landscape where Evolutionary Genomics can leverage its unique technology to gain market share.
Clientes Clave
- Governmental organizations seeking advancements in agricultural research.
- Non-profit foundations focused on food security and sustainability.
- Commercial entities in the agriculture sector looking for genetic enhancements.
Finanzas
Gráfico e información
Precio de la acción de Evolutionary Genomics, Inc. (FNAM): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para FNAM.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para FNAM.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para FNAM.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de FNAM en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Steve Warnecke
CEO
Steve Warnecke has led Evolutionary Genomics, Inc. since its inception in 1990. With a background in biotechnology and genetics, he has been instrumental in establishing the company's research focus and developing its proprietary technologies. His leadership is marked by a commitment to advancing agricultural science through innovative genetic solutions.
Historial: Under Steve's leadership, Evolutionary Genomics has developed its Adapted Traits Platform, positioning the company as a key player in agricultural biotechnology. His strategic decisions have led to collaborations with various governmental and non-profit organizations, enhancing the company's visibility in the sector.
Información del mercado OTC de FNAM
The OTC Other tier includes companies that do not meet the listing requirements of the major exchanges like NYSE or NASDAQ. These companies may have less liquidity and less stringent reporting requirements, making them riskier investments.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosures may hinder investor confidence.
- Low trading volume can lead to higher volatility and difficulty in executing trades.
- Regulatory risks associated with biotechnology research and product development.
- Verify the company's financial health and operational metrics.
- Assess the competitive landscape and market positioning.
- Review any partnerships or collaborations that enhance its market reach.
- Investigate the regulatory environment affecting its research and products.
- Confirm the credibility of the management team and their track record.
- Established in 1990, indicating a long-standing presence in the industry.
- Focus on research and partnerships with governmental and non-profit organizations.
- Development of proprietary technology in agricultural biotechnology.
FNAM Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar FNAM?
Evolutionary Genomics, Inc. (FNAM) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Innovative Adapted Traits Platform for genetic research.. Riesgo principal a monitorear: Potential: Regulatory challenges that could delay research and product development.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de FNAM?
FNAM actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de FNAM?
Los precios de FNAM se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre FNAM?
La cobertura de analistas para FNAM incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en FNAM?
Las categorías de riesgo para FNAM incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory challenges that could delay research and product development.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de FNAM?
La relación P/E para FNAM compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está FNAM sobrevalorada o infravalorada?
Determinar si Evolutionary Genomics, Inc. (FNAM) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de FNAM?
Evolutionary Genomics, Inc. (FNAM) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited financial data available for comprehensive analysis.